GPR6 antagonists
State of the art
No update yet for GPR6 antagonists. An update is a standalone state-of-the-art for the topic — what someone with Parkinson's needs to know about where this approach stands today.
-
Phase 3 trial of solengepras for Parkinson’s disease now fully enrolled
Solengepras (CVN424) is a first-in-class oral GPR6 receptor antagonist targeting striatal neurons; with Phase 3 enrollment complete and readout expected late 2026, it represents a novel non-dopaminergic mechanism that could reach patients if Phase 3 data confirm Phase 2 results.